We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Qiagen Opens Subsidiary in Hong Kong

By Labmedica staff writers
Posted on 07 Aug 2007
Qiagen NV (Hamburg, Germany), a provider of molecular diagnostics, sample and assay technologies, and applied testing has officially opened a new subsidiary in Hong Kong. The location will serve as the company's center for further business expansion in the region.

"Hong Kong is a focal point for science, healthcare, and the fast developing market for biomedical research,” said Dr. Frauke Ehlert, general manager of Qiagen China & Hong Kong. With growth rates of over 60%, Asia today is the company's fastest growing marketplace. The company maintains 12 Asian offices with approximately 300 employees.

Qiagen's business activities in Asia address the growing demand for solutions in diagnostics and life science research. The company provides molecular diagnostic and testing systems for infectious diseases. Demographic developments and the further growth of middle classes in many Asian countries are spurring the demand for diagnostic solutions and also catalyzing increased investments in science.

Qiagen Asia, headquartered in Shanghai, was established in 2006 as one of the company's regional organizations. Products to customers in Taiwan, India, Thailand, and Vietnam are sold via local distributors; Japan has its own entity within the Qiagen organization.


Related Links:
Qiagen

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Prefilled Tubes
Prefilled 5.0ml Tubes

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
07 Aug 2007  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
07 Aug 2007  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
07 Aug 2007  |   Industry



PURITAN MEDICAL